Dr. Tom Fitch
Add to your Care-Team
Dr. Tom Fitch
Dr. Tom Fitch
Internal Medicine - Oncology
I specialize in
Internal Medicine - Oncology
Internal Medicine - Hematology
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
University of Kansas School of Medicine
University of Kansas
Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer.
Am. J. Clin. Oncol., Dec (2012)
The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9.
Support Care Cancer., Nov (2012)
North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane.
Clin. Breast Cancer., Dec;12(6):387-91 (2012)
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Clin. Breast Cancer., Apr;12(2):81-6 (2012)
Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.
Radiat Oncol., 6:91 (2011)
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Clin Colorectal Cancer., Mar;11(1):31-7 (2012)
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Cancer., Apr;117(8):1704-10 (2011)
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Am. J. Clin. Oncol., Aug;35(4):329-33 (2012)
Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors.
J Thorac Oncol., Dec;5(12):1994-8 (2010)
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
J. Clin. Oncol., Nov;28(33):4877-83 (2010)
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Int. J. Radiat. Oncol. Biol. Phys., Oct;81(2):476-82 (2011)
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).
Ann. Oncol., Oct;21(10):2040-4 (2010)
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
J Clin Pharmacol., Mar;50(3):268-75 (2010)
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
J. Clin. Oncol., Jun;27(17):2848-54 (2009)
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
Ann. Oncol., Mar;20(3):542-9 (2009)
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Cancer., Jan;115(1):119-27 (2009)
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
J. Clin. Oncol., Jan;27(1):11-5 (2009)
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
J Gastrointest Cancer., 38(2-4):87-94 (2007)
Decision-making role preferences of patients receiving adjuvant cancer treatment: a university of Rochester cancer center community clinical oncology program.
Support Cancer Ther., Jan;1(2):119-26 (2004)
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Lung Cancer., May;60(2):200-7 (2008)
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
Am. J. Clin. Oncol., Oct;30(5):507-13 (2007)
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
Cancer., Sep;110(6):1396-403 (2007)
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Am J Ther., 13(4):291-7 (2006 Jul-Aug)
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
J. Clin. Oncol., Jun;24(18):2836-41 (2006)
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
Mayo Clin. Proc., Jun;81(6):758-67 (2006)
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
Int. J. Radiat. Oncol. Biol. Phys., Jul;65(4):1106-11 (2006)
Metastatic prostate carcinoma mimicking meningioma: case report and review of the literature.
Neurologist., Jan;12(1):48-52 (2006)
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
J. Clin. Oncol., Mar;24(9):1409-14 (2006)
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.
Haematologica., Mar;91(3):390-3 (2006)
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Ann. Oncol., Feb;17(2):226-31 (2006)
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Ann. Oncol., Jan;17(1):29-34 (2006)
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.
J Palliat Med., Oct;8(5):924-30 (2005)
5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.
Lancet Oncol., Oct;6(10):765-72 (2005)
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
J. Clin. Oncol., Sep;23(25):5929-37 (2005)
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Oncology., 69(2):117-21 (2005)
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Int. J. Radiat. Oncol. Biol. Phys., Feb;61(2):380-6 (2005)
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
J. Clin. Oncol., Dec;22(24):4944-50 (2004)
Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices.
Cancer., Aug;101(4):851-7 (2004)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
J. Clin. Oncol., Jul;22(14):2849-55 (2004)
Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity.
Lung Cancer., Mar;43(3):345-53 (2004)
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Clin. Cancer Res., Dec;3(12 Pt 1):2363-70 (1997)
Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Am. J. Clin. Oncol., Oct;20(5):500-4 (1997)
Dr. Tom Fitch M